Duration of anticoagulant therapy after initial idiopathic venous thromboembolism

Annals of Pharmacotherapy

Volumn 37, Issue 10, 2003, Pages 1489-1496

  Frazee, Lawrence A ^a,b   Chomo, Diane L ^b,c  

^a AKRON GENERAL MEDICAL CENTER   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c Internal Medicine Center of Akron   (United States)

Author keywords

Anticoagulation; Duration of therapy; Idiopathic venous thromboembolism; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG DOSE REDUCTION; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; LONG TERM CARE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK FACTOR; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS;

AMBULATORY CARE; ANTICOAGULANTS; HUMANS; META-ANALYSIS; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0141557896     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C486     Document Type: Review

References (38)

1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158:585-93.
2. Hansson PO, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. "The Study of Men Born in 1913." Arch Intern Med 1997; 157:1665-70.
3. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2002; 162:1245-8.
4. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222-31.
5. Thomas RH. Hypercoagulability syndromes. Arch Intern Med 2001; 161: 2433-9.
6. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 1999;159:445-53.
7. Mohr DN, Silverstein MD, Heit JA, Petterson TM, O'Fallon WM, Melton LJ III. The venous stasis syndrome after deep venous thromboembolism or pulmonary embolism: a population-based study. Mayo Clin Proc 2000;75:1249-56.
8. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villata S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
9. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, et al., and the Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-8.
10. Kearon C, Hirsch J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997;336:1506-11.
11. Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Larfars G, Nicol P, et al., and the Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332: 1661-5.
12. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119(suppl 1):176S-93S.
13. Levine JS, Branch W, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63.
14. The Haemostasis and Thrombosis Task Force of the British Society for Haematology. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109:704-15.
15. Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH, et al. The risk of recurrent venous thromboembolism in patients with an Arg506 - Gin mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336:399-403.
16. Eichinger S, Weltermann A, Mannhalter C, Minar E, Bialonczyk C, Hirschl M, et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 2002;162:2357-60.
17. Prandoni P, Lensing AWA, Buller HR, Cogo A, Prins MH, Cattelan AM, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-33.
18. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Dureu I, et al., and the Duree Optimale du Traitement Anti Vitamines K (DOTAVK) Study Group. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf vein thrombosis. Circulation 2001;103:2453-60.
19. Ridker PM, Miletich JP, Stampfer MJ, Goldgaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995;92:2800-2.
20. Rintelen C, Pabinger I, Knobl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996;75:229-32.
21. Eichinger S, Pabinger I, Stumpflen A, Hirschl M, Bialonczyk C, Schneid B, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997;624:624-8.
22. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Wiman B, Egberg N, et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene: DURAC Trial Study Group. Thromb Haemost 1999;81:84-9.
23. Kearon C, Gent M, Hirsch J, Weitz J, Kovacs MJ, Anderson DR, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-7.
24. DeStefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999;341:801-6.
25. Margaglione M, D'Andrea G, Colaizzo D, Cappucci G, del Popolo A, Brancaccio V, et al. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 1999;82:1583-7.
26. Prandoni P, Lensing, AWA, Prins MH, Bernardi E, Marchiori A, Bagatella P, et al. Residual thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2003;137:955-60.
27. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992;340:873-6.
28. AbuRahma AF, Stickler DL, Robinson PA. A prospective controlled study of the efficacy of short-term anticoagulation therapy in patients with deep vein thrombosis of the lower extremity. J Vasc Surg 1998; 28:630-7.
29. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165-9.
30. Levine MN, Hirsch J, Gent M, Turpie AG, Weitz J, Ginsberg J, et al. Optimal duration of anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995;74:606-11.
31. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, et al. Long-term low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-34.
32. O'Sullivan EF. Duration of anticoagulant therapy in venous thromboembolism. Med J Aust 1972;2:1104-7.
33. Schulman S, Lockner D, Juhlin Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis: a randomized study. Acta Med Scand 1985;217:547-52.
34. Holmgren KA, Andersson G, Fagrell B, Johnsson H, Ljungberg B, Nilsson E, et al. One-month versus six months therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985;218:279-84.
35. Fennerty AG, Dolben J, Thomas P, Backhouse G, Bentley DP, Campbell IA, et al. A comparison of 3 and 6 weeks' anticoagulation in the treatment of venous thromboembolism. Clin Lab Haematol 1987;9:17-21.
36. Fennerty AG, Campbell IA, Routledge PA. Anticoagulants in venous thromboembolism. Guidelines for optimum treatment. BMJ 1988;297:1285-8.
37. Pinede L, Duhaut P, Cucherat M, Ninet J, Pasquier J, Boissel JP. Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized controlled trials. J Intern Med 2000;247:553-62.
38. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-9.